\contentsline {section}{\numberline {1}Introduction}{4}{section.1}%
\contentsline {section}{\numberline {2}Purpose and scope of the guideline}{5}{section.2}%
\contentsline {section}{\numberline {3}Architectural context and national motivation}{5}{section.3}%
\contentsline {section}{\numberline {4}Design principles for evidence-based variant interpretation}{5}{section.4}%
\contentsline {section}{\numberline {5}Data provenance and sample quality requirements}{5}{section.5}%
\contentsline {section}{\numberline {6}Evidence rule framework}{5}{section.6}%
\contentsline {subsection}{\numberline {6.1}Structure of evidence rules}{5}{subsection.6.1}%
\contentsline {subsection}{\numberline {6.2}Versioning and audit trace}{5}{subsection.6.2}%
\contentsline {subsection}{\numberline {6.3}Optional reference implementation (QV framework)}{5}{subsection.6.3}%
\contentsline {subsection}{\numberline {6.4}Implemented rule set}{9}{subsection.6.4}%
\contentsline {section}{\numberline {7}Evidence flags}{10}{section.7}%
\contentsline {subsection}{\numberline {7.1}Evidence domains}{10}{subsection.7.1}%
\contentsline {subsection}{\numberline {7.2}Final flag set}{11}{subsection.7.2}%
\contentsline {subsection}{\numberline {7.3}Interpretation of flag combinations}{12}{subsection.7.3}%
\contentsline {section}{\numberline {8}Structured representation and interoperability}{12}{section.8}%
\contentsline {subsection}{\numberline {8.1}Alignment with GA4GH Variant Representation and Variant Annotation models}{12}{subsection.8.1}%
\contentsline {subsection}{\numberline {8.2}GA4GH Variant Annotation model}{12}{subsection.8.2}%
\contentsline {subsection}{\numberline {8.3}Exchange formats and machine readable outputs}{14}{subsection.8.3}%
\contentsline {section}{\numberline {9}Probabilistic interpretation in Pillar 3}{14}{section.9}%
\contentsline {subsection}{\numberline {9.1}Relationship to Pillar 1 and Pillar 2 inputs}{14}{subsection.9.1}%
\contentsline {subsection}{\numberline {9.2}Evidence aggregation logic}{14}{subsection.9.2}%
\contentsline {section}{\numberline {10}Clinical review checkpoints}{14}{section.10}%
\contentsline {subsection}{\numberline {10.1}Required manual assessments}{14}{subsection.10.1}%
\contentsline {subsection}{\numberline {10.2}Boundary of automated reasoning}{14}{subsection.10.2}%
\contentsline {section}{\numberline {11}Reporting and synthesis statements}{14}{section.11}%
\contentsline {section}{\numberline {12}Auditability, versioning, and reproducibility}{14}{section.12}%
\contentsline {section}{\numberline {13}Limitations and scope}{14}{section.13}%
\contentsline {section}{\numberline {14}Future extensions}{14}{section.14}%
\contentsline {section}{\numberline {15}Conclusion}{14}{section.15}%
\contentsline {section}{\numberline {16}Supplemental}{17}{section.16}%
\contentsline {section}{\numberline {17}Appendix}{17}{section.17}%
\contentsline {subsection}{\numberline {17.1}Example rule files}{17}{subsection.17.1}%
\contentsline {subsection}{\numberline {17.2}Example YAML or JSON evidence objects}{17}{subsection.17.2}%
\contentsline {subsection}{\numberline {17.3}Worked examples of flagged variants}{17}{subsection.17.3}%
\contentsline {section}{\numberline {18}Evidence flags}{17}{section.18}%
\contentsline {subsection}{\numberline {18.1}Evidence domains}{17}{subsection.18.1}%
\contentsline {subsubsection}{\numberline {18.1.1}Counter-evidence and conflict handling}{17}{subsubsection.18.1.1}%
\contentsline {subsubsection}{\numberline {18.1.2}Normalised variant representation and nomenclature}{17}{subsubsection.18.1.2}%
\contentsline {subsubsection}{\numberline {18.1.3}ACMG criteria with counter-factual evidence}{18}{subsubsection.18.1.3}%
\contentsline {subsubsection}{\numberline {18.1.4}Population frequency evidence}{19}{subsubsection.18.1.4}%
\contentsline {subsubsection}{\numberline {18.1.5}Conditional evidence rules and source-dependent quality checks}{19}{subsubsection.18.1.5}%
\contentsline {subsubsection}{\numberline {18.1.6}Inheritance and segregation evidence}{19}{subsubsection.18.1.6}%
\contentsline {subsubsection}{\numberline {18.1.7}Functional and molecular evidence}{21}{subsubsection.18.1.7}%
\contentsline {subsubsection}{\numberline {18.1.8}Phenotype and geneâ€“disease validity evidence}{21}{subsubsection.18.1.8}%
